# A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

> **NCT02633657** · PHASE1 · WITHDRAWN · sponsor: **XenoPort, Inc.**

## Conditions studied

- RLS

## Interventions

- **DRUG:** HORIZANT 300 mg

## Key facts

- **NCT ID:** NCT02633657
- **Lead sponsor:** XenoPort, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01
- **Primary completion:** 2017-07-19
- **Final completion:** 2017-07-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of enrollment
- **Last updated:** 2021-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633657, "A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02633657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*